Tesaro licenses worldwide rights to Amgen ALK inhibitors for cancer
This article was originally published in Scrip
Executive Summary
Privately held Tesaro has licensed exclusive worldwide rights from Amgen to develop, manufacture, commercialize and distribute anaplastic lymphoma kinase (ALK) inhibitors for oncology indications, including ALK-positive non-small-cell lung cancer (NSCLC).